Starting a GLP-1 receptor agonist (semaglutide — Ozempic® / Wegovy®) or dual GIP/GLP-1 agonist (tirzepatide — Mounjaro® / Zepbound®) triggers a major shift in gastric motility and hypothalamic satiety signaling during the first 4 to 8 weeks.

Why Do Gastrointestinal Side Effects Happen?

GLP-1 medications intentionally slow down gastric emptying. When meal volume remains too large or high in dietary fat during the 24h–72h peak plasma concentration window (Cmax), patients experience mild nausea, fullness, reflux, or constipation.

4 Evidence-Based Habits for Smooth Adaptation